April 01, 2025

FDA Monthly Round-Up: Key March Updates

March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.

Conexiant

April 01, 2025

FDA Approves Freeze-Dried Jynneos Vaccine

Bavarian Nordic’s freeze-dried Jynneos vaccine offers logistical advantages over the liquid-frozen version, supporting long-term U.S. stockpiling and public health preparedness.

Conexiant

April 01, 2025

Cemiplimab Effective for Advanced cSCC

Meta-analysis of 19 studies reveals promising 54.5% objective response rate and manageable safety profile for PD-1 inhibitor in treating advanced cutaneous squamous cell carcinoma.

Conexiant

March 31, 2025

Tariff Threat: Drugs Could Cost U.S. $750M More

New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.

Conexiant

March 31, 2025

Parker Institute for Cancer Immunotherapy Names New CEO

The Parker Institute for Cancer Immunotherapy announced the appointment of Karen E. Knudsen, MBA, PhD, as its new Chief Executive Officer (CEO).

The ASCO Post

March 26, 2025

State Eyes New Tools to Bolster Health Workforce

Proposals include licensure for community health workers, expanded provider roles, and Medicaid coverage adjustments to address staffing gaps and access barriers.

KFF Health News

March 26, 2025

Stem Cell Transplant May Not Be Necessary in First Remission for Patients With Mantle Cell Lymphoma and Undetectable MRD

Autologous stem cell transplantation (ASCT) does not improve survival outcomes for patients with mantle cell lymphoma who achieve a deep first complete remission with undetectable measurable residual ...

The ASCO Post

March 25, 2025

Microplastics: Chewing Gum May Release Particles Into Saliva

"Surprisingly, both synthetic and natural gums had similar amounts of microplastics released when we chewed them."

Conexiant

March 24, 2025

TPT Lowers Tuberculosis Risk in Rheumatic Patients

TPT decreased the overall risk of tuberculosis disease in patients with rheumatic diseases, with a 76% risk reduction observed in certain subgroups, researchers reported.

Conexiant